ALBIO Biosynex SA
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products, as well as anti-mosquito bracelets and waterproof, moisturizing, and sensitive skin spray. The company was incorporated in 2005 and is based in Illkirch-Graffenstaden, France.…
Industry Peers
Medical DevicesKey Statistics
About Biosynex (EPA: ALBIO)
›
Biosynex (EPA: ALBIO) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 397 employees.
The shares were at 0.7960 EUR on 19 November 2026, up 53.1% over 52 weeks. Its 52-week range is 0.4550 EUR to 1.570 EUR: the price is 49.3% below the high and 74.9% above the low.
Its market capitalisation is 14.67M EUR.
Biosynex reports return on equity of -166.6%, an operating margin of 17.4% and revenue down 5.8% year over year.
Its debt exceeds its cash by 53.19M EUR, a debt-to-equity ratio of 1.76. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.